COVID-19 Coronavirus

Humanigen Downfall: FDA Rejection For COVID-19 Drug Triggers Financial Crisis, Bankruptcy
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand
Privatized Vaccine Distribution Sparks Confusion, Payment Challenges
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute

COVID-19 Coronavirus Recent News

Moderna Talks Offer Hope for Enhanced COVID-19 Vaccine Availability In Europe
European countries are actively negotiating a fresh COVID-19 vaccine procurement agreement with Moderna Inc (NASDAQ: MRNA) as concerns mount within EU health authorities regarding a surge in coronavirus infections. 
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
Updated Covid Vaccine US Rollout Hit by Insurance Coverage Delays - What It Means?
As the U.S.
Say Goodbye to Free COVID-19 Shots: CDC Approves Priced Boosters for Omicron Subvariants
The Centers for Disease Control and Prevention (CDC) has officially endorsed COVID-19 booster shots for individuals six months and older as we approach the fall season.
Is Moderna's New Vaccine the Answer to the Highly Mutated BA.2.86 COVID-19 Variant?
Moderna Inc's (NASDAQ: MRNA) clinical trial data from its research assay confirm that its updated COVID-19 vaccine generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86 (Pirola), 
Europe Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination Campaigns
The European Commission has approved Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech SE (NASDAQ:
Money Stolen On Account COVID-19 Relief Fund Fraud is Shocking! US Justice Department Cracks Whip
The U.S.
Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies
Moderna Inc (NASDAQ: MRNA) announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against 
Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People
Virios Therapeutics Inc (NASDAQ: VIRI) announced that female patients diagnosed with Long-COVID illness exhibited clinically and statistically significant improvements related to Long-COVID when treated open-label with a combination of valacyclovir and celecoxib (Val/Cel) for 14 weeks, 
Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People
Invivyd Inc (NASDAQ: IVVD) announced additional initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal 
Pfizer's COVID-19 Pill Paxlovid Underutilized in Nursing Homes Despite Proven Efficacy
Elderly and frail nursing home residents, who could have significantly benefited from antiviral treatments for COVID-19, received inadequate amounts of the medication following their coronavirus infections, even when Pfizer Inc's (NYSE: PFE) Paxlovid pill was readily available.
Novavax's COVID-19 Vaccine Gets Complete Approval From European Commission
The European Commission has approved Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373), following a positive opinion for a full authorization from the Committee for Medicinal Products for Human Use of the 
Moderna Seeks European Nod For Updated COVID-19 Vaccine Shot To Tackle New Dominant Strain
Moderna Inc (NASDAQ: MRNA) submitted a regulatory application to the European Medicines Agency (EMA) for its updated COVID-19 vaccine encoding the spike protein for the XBB.1.5 
Merck, Ridgeback Withdraw COVID-19 Pill European Application Amid Regulatory Hurdles
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have reportedly withdrawn their COVID-19 pill application in the European Union (EU).
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other pandemics or to support vaccine manufacturing in Africa. The initiative will conclude at the end of this year, but some of its work will continue.
Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19
Invivyd Inc (NASDAQ: IVVD) announces initial data from its ongoing Phase 1 healthy volunteer clinical trial of VYD222, its investigational monoclonal 
Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support
Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members v
Cue Health Becomes First Company to Receive FDA De Novo Authorization COVID-19 Home Use Test
Cue Health Inc (NASDAQ: HLTH) became the first company to receive De Novo authorization from the FDA for its Cue COVID-19 Molecular Test, designed for both home and 
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging coronavirus variants prevalent in the U.S.
BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases
In an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told shareholders the company is working on COVID-19 vaccines targeting XBB.1.5 strains in line with recommendations by the World Health Organization.
GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the